CXCL10 and CXCL11 are ligands of chemokine CXCR3, which can regulate the migration, differentiation and activation of immune cells, and are related to the selective migration and linear development of CD4 + and CD8 + T cells (Karin and Razon, 2018), thereby affecting the therapeutic effect of cancer (Tokunaga et al., 2018). Here, CD8A is linked to cancer.